Garadacimab clinical trials
Also written CSL312.
How each study uses garadacimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Jun 2025 · ANDEMBRY · BLA 761367 (FDA, Drugs@FDA)
- European Union
- 10 Feb 2025 · Andembry · EMEA/H/C/006116 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses garadacimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompletedPhase 4CSL BehringNCT06806657Written as Garadacimab
- CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaCompletedPhase 3CSL BehringNCT05819775Written as CSL312
- Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksCompletedPhase 3CSL BehringNCT04739059Written as CSL312
- Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisCompletedPhase 2CSL BehringNCT05130970Written as Garadacimab
- CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema AttacksCompletedPhase 3CSL BehringNCT04656418Written as CSL312
- A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)CompletedPhase 2CSL BehringNCT03712228Written as Factor XIIa antagonist monoclonal antibody
- A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy SubjectsCompletedPhase 1CSL BehringNCT05306275Written as CSL312
- A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian AdultsCompletedPhase 1CSL BehringNCT04580654Written as CSL312
- A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC LineWithdrawnPhase 1/2CSL BehringNCT04281524Written as CSL312
Codes
What other systems call garadacimab · ClinicalTrials.gg INT002144
- MeSH (NLM) C000731822garadacimabOne source NLM
- UNII (FDA) 32W6AJL0DYGARADACIMABConfirmed FDA, NLM
- NCI Thesaurus C166633GaradacimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731822 | garadacimab | One source NLM |
| UNII (FDA) | 32W6AJL0DY | GARADACIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C166633 | Garadacimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.